Table 1 Clinical characteristics of patients with postmenopausal osteoporosis and glucocorticoid-induced osteoporosis
| Â | Postmenopausal osteoporosis (n = 72) | Glucocorticoid-induced osteoporosis (n = 225) | p value |
|---|---|---|---|
Premenopausal (%) | Â | 144 (64) | Â |
Postmenopausal (%) | 72 (100) | 81 (36) | Â |
Age (years) | 76.4 (8.16) | 49.7 (15.6) | < 0.0001*** |
Height (cm) | 148.4 (8.42) | 156.5 (7.07) | < 0.0001*** |
Bodyweight (kg) | 48.2 (8.4) | 53.3 (11.1) | 0.013* |
Body mass index | 21.9 (3.45) | 21.8 (4.08) | 0.71 |
Bone mineral density (g/cm2) | Â | Â | Â |
 Lumbar spine | 0.775 (0.118) | 0.884 (0.13) | < 0.0001*** |
 Femoral neck | 0.541 (0.12) | 0.654 (0.118) | < 0.0001*** |
 Total hip | 0.639 (0.114) | 0.753 (0.125) | < 0.0001*** |
 Vertebral fracture (%) | 30 (41.7) | 62 (27.6) |  |
Medical conditions necessitating glucocorticoid therapy | Â | Â | Â |
 Rheumatoid arthritis (%) |  | 57 (25.3) |  |
 Systemic lupus erythematosus (%) |  | 148 (65.8) |  |
 Others (%) |  | 20 (8.9) |  |
Disease duration (years) | Â | 15.9 (10.5) | Â |
Disease duration subtracted from age (years) | Â | 33.7 (14.8) | Â |
Glucocorticoid treatment duration (years) | Â | 14.4 (10.1) | Â |
Daily prednisone-equivalent dose (mg) | Â | 8.1 (3.42) | Â |
Cumulative prednisone-equivalent dose (g) | Â | 402.9 (387.6) | Â |
Treatment for osteoporosis | Â | Â | Â |
 Bisphosphonate (%) | 61 (84.7) | 172 (76.4) |  |
 Denosumab (%) | 11 (15.3) | 53 (22.6) |  |